The bugs are outrunning the drugs. The counterattack is phages, maps and vaccines
A phage cocktail that covers most drug-resistant Klebsiella, a new cholera phage, surging drug-resistant TB in Brazil and a returning pneumococcal strain in Catalonia.
- 14 capsular types dominate drug-resistant Klebsiella circulation and account for 67-77% of the global burden; a repository of 48 lytic phages covers all 14, in a preprint. Self-reported m:…1218
- MAA01, a new phage isolated from Haiti, has a 31,507 base-pair genome and 47 genes and reduces cholera bacterial load 4-fold in an infant mouse model, in a preprint. Self-reported m:…1466
- Multidrug-resistant tuberculosis cases in Brazil grew 294% to 574% between 2017 and 2021 across high-risk populations, in a preprint. Self-reported m:…1545
- Pneumococcal serotype 14 reached 10.8% incidence in Catalonia in 2025, and only 18.8% of patients with serotype 14 disease were appropriately vaccinated, in a preprint. Self-reported m:…0807
What changed
Four papers describe the same problem from four directions: infections that drugs no longer reliably stop, and diseases that had receded coming back. The papers cover drug-resistant Klebsiella pneumoniae, cholera, multidrug-resistant tuberculosis in Brazil, and pneumococcal disease in Catalonia. Two of them propose phages, viruses that kill bacteria, as the countermeasure. The other two are surveillance: careful counts of what is actually circulating, and who it is hitting. All four are preprints, so none of the results has been peer reviewed. m:…1218 m:…1466 m:…1545 m:…0807
Phages, aimed by surveillance
The most developed countermeasure is a phage cocktail aimed at carbapenem-resistant Klebsiella pneumoniae. Fourteen capsular locus types dominate contemporary circulation of the resistant bacterium and account for 67 to 77% of the global burden, the paper reports. A repository of 48 lytic phages can be organized into capsule-defined modules to cover all 14 dominant types, and capsular typing alone is sufficient to assign effective phage modules, bypassing the need for isolate-level matching. That last point is the practical one: if the capsule type is enough to pick the treatment, a hospital does not need to match phages to each patient's isolate first. The paper also reports that the strain background had no significant effect on phage efficacy in 12 of 14 tested capsular types. m:…1218
A second phage paper reports a new bacteriophage, MAA01, isolated from Haiti, with a 31,507 base-pair genome and 47 genes. It targets the O1 lipopolysaccharide antigen of Vibrio cholerae, the bacterium that causes cholera, and it reduces the cholera bacterium's load by 4-fold in an infant mouse model. The paper notes a curiosity: MAA01 shows a virulent phenotype against Vibrio cholerae despite possessing a temperate genome. A mouse model is not a patient, and a fourfold reduction in bacterial load is a laboratory result, not a treatment, but a phage that works in a living animal is further along than one that only works in a dish. m:…1466
The old diseases are moving
The two surveillance papers are less encouraging. In Brazil, multidrug-resistant tuberculosis cases grew by 294% to 574% between 2017 and 2021 across high-risk populations. Treatment abandonment, coinfection, social vulnerability, and occupational exposure are the key determinants the authors identify for the spread, and they conclude that current public health policies in Brazil are insufficient to control multidrug-resistant tuberculosis in high-risk populations. In Catalonia, pneumococcal serotype 14 reached 10.8% incidence in 2025, driven by multiple established lineages, GPSC6, GPSC18, GPSC16 and GPSC39, rather than a novel clone, and 56.3% of patients with serotype 14 disease had comorbidities while only 18.8% were appropriately vaccinated. m:…1545 m:…0807
Why it matters
The four papers point in the same direction, and it is not toward a new antibiotic. The countermeasures on offer are knowledge: which capsule types dominate, which phage kills which bacterium, which lineages are circulating, and who is unvaccinated. The Klebsiella cocktail is designed around surveillance, with the capsule types chosen because they dominate circulation, and the Catalonia paper is explicit that the return of serotype 14 is a failure of protection, not the arrival of something new. The open question is whether phage cocktails can move from repositories and mouse models into hospitals at the speed the resistance numbers suggest they need to, and whether the surveillance findings change vaccination and treatment policy in the places the papers studied. m:…1218 m:…0807 m:…1545 m:…1466
What is still unresolved
- All four papers are preprints; the phage results are preclinical and the surveillance counts have not been peer reviewed.
- Whether capsular typing alone works as well in hospitals as the Klebsiella paper's tests suggest is unproven in patients.
- The Brazil paper does not show what policy change would reverse the multidrug-resistant tuberculosis growth it reports.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.